BIA blog

CEO Update | 3 October 2022

We’ve moved out of our offices to enable the demolition of the Southside building in Victoria street. We are currently in interim offices and our new address is BioIndustry Association, LABs, Victoria House, Bloomsbury Way, London, WC1B 4DA. We say goodbye to Southside after over 11 years... Read on for an update on the Conservative Party and Labour Party conferences, Board Elections and TechBio UK Conference.

Member Spotlight: Interview with Moderna

Following the announcement about the BioIndustry Association (BIA) reaching a new milestone of 500 member companies earlier this week, we spoke with Darius Hughes, UK General Manager at Moderna to learn more about the mRNA global player and his intentions behind joining the trade association’s membership.

CEO Update | 26 September 2022

Chancellor highlights the globally leading role of the life science sector in Friday’s mini-budget and launches a new UK TIBI-like investment initiative for innovative firm financing and sad news about former BIA CEO Aisling Burnand. Read on for updates on the party conferences, BIA events, Annual General Meeting and Board Elections plus our new office location.

bioProcessUK spotlight: All data great and small

Ahead of the 19th annual bioProcessUK conference (15-17 November, Edinburgh), we spoke to Simon Simpkins PhD, VP, Head of Operational Strategy at Oxford Biomedica about the company's digital future, where the foundational concept of good data management underpins all aspirations. But how do you build that integrated vision and keep the business running at the same time?

 

Press Releases

BIA celebrates breaking 500 members after Moderna enters membership

The BioIndustry Association (BIA) today has announced that its membership has passed 500 companies, as mRNA global player Moderna entered into the trade association’s membership.

Mini-Budget positions UK life sciences to drive new government's economic growth agenda

The Chancellor of the Exchequer today announced at the mini-Budget the Long-Term Investment for Technology & Science (LIFTS) competition. This will provide up to £500 million to support new funds designed to catalyse investment from pensions schemes and other investors into the UK’s pioneering science and technology businesses, this is a direct result of the life science scale up agenda that the BIA has championed and worked closely with government on.

Genomics drives UK life science success, new report finds

Genomics companies outperform their life science peers at attracting both public and private investment according to a new report. New data shows that UK genomics companies raised £1.9 billion of venture investment and £35.7 million in public grants since 2017, demonstrating the strength of this innovative sector.

UK R&D tax relief remains highly supportive of life sciences following BIA campaign

The UK’s R&D tax relief regime will continue to support innovative life sciences and biotech companies to conduct essential clinical trials and some pre-clinical work overseas following the publication of new draft legislation. However, some concerns remain, with further clarifications and guidance needed, says the sector’s trade association.

 

Member News

BioIVT Announces Global eCommerce Collaboration With Charles River Laboratories Avian Vaccine Services

Charles River Avian products, which are used for virus research and to produce veterinary and human vaccines, are now available through the BioIVT Digital Portal.

New Kent partnership to supercharge STEM talent and enterprise of tomorrow

A leading university in the Kent and Medway region and the county’s largest science and innovation park have announced they are taking their collaboration to a whole new level.

Stablepharma and BB-NCIPD Ltd (Bul Bio) sign exclusive supply agreement to produce the world’s first fridge-free Tetanus diphtheria vaccine

Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) European vaccine manufacturer, are delighted to announce that we have signed a definitive agreement for the exclusive bulk supply and commercialisation of the Tetanus diphtheria vaccine, on September 20th, 2022.

Astrea Bioseparations introduces Nereus LentiHERO™, a fit-for-purpose solution for lentiviral vector purification

First commercially available product to utilize AstreAdept, Astrea Bioseparations’ novel nanofiber-based membrane material

 

Our publications

Here's a selection of featured BIA publications. See Resources Hub  

Regulating artificial intelligence

Artificial intelligence (AI) is becoming embedded in our daily lives, and that includes the life science sector. Both the UK Government and the EU are grappling with how to regulate this innovative technology. Dr Emma Lawrence outlines the approaches being taken by the UK and EU and how these might affect BIA members.

BIA submission to the Labour start-up review

The life sciences and biotech sector plays a significant part in furthering many of the Labour Party’s ambitions for the UK, including rebooting economic growth, providing high-wage jobs and levelling-up opportunities across all parts of the country, delivering Net Zero and improving the health of the nation.